Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.

Also called NCT05585606

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (enrolled count) (from the registry)
Sponsor
Silver Creek Pharmaceuticals (from the registry)
Registry
  • NCT NCT05585606
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05585606. Randomized; quadruple masking; primary purpose treatment. Start 2022-10-19 (actual); primary completion 2025-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke
Acronym
ARPEGGIO
Condition
Acute Ischemic Stroke (AIS)
Intervention (Drug)
Placebo
Intervention (Drug)
scp776 (1.9 mg/kg)
Intervention (Drug)
scp776 (3.8 mg/kg)
Intervention (Drug)
scp776 (4.8 mg/kg)
Intervention (Drug)
scp776 (all dose levels)
Lead sponsor
Silver Creek Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05585606
Content hash
8febfdc3f58378f932a3b54b3d3a6d714f6a5f9d523f89eb2f989d2578934d31